EP1185558A4 - Peptide having preptin functionality - Google Patents

Peptide having preptin functionality

Info

Publication number
EP1185558A4
EP1185558A4 EP00942575A EP00942575A EP1185558A4 EP 1185558 A4 EP1185558 A4 EP 1185558A4 EP 00942575 A EP00942575 A EP 00942575A EP 00942575 A EP00942575 A EP 00942575A EP 1185558 A4 EP1185558 A4 EP 1185558A4
Authority
EP
European Patent Office
Prior art keywords
preptin
peptide
functionality
preptin functionality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00942575A
Other languages
German (de)
French (fr)
Other versions
EP1185558A1 (en
Inventor
Garth James Smith Cooper
Christina Maree Buchanan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
PROTEMIX DISCOVERY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROTEMIX DISCOVERY Ltd filed Critical PROTEMIX DISCOVERY Ltd
Publication of EP1185558A1 publication Critical patent/EP1185558A1/en
Publication of EP1185558A4 publication Critical patent/EP1185558A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP00942575A 1999-06-18 2000-06-19 Peptide having preptin functionality Withdrawn EP1185558A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ33635999 1999-06-18
NZ33635999 1999-06-18
PCT/NZ2000/000102 WO2000078805A1 (en) 1999-06-18 2000-06-19 Peptide having preptin functionality

Publications (2)

Publication Number Publication Date
EP1185558A1 EP1185558A1 (en) 2002-03-13
EP1185558A4 true EP1185558A4 (en) 2006-02-15

Family

ID=19927343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00942575A Withdrawn EP1185558A4 (en) 1999-06-18 2000-06-19 Peptide having preptin functionality

Country Status (7)

Country Link
EP (1) EP1185558A4 (en)
JP (1) JP2003503019A (en)
CN (1) CN1296384C (en)
AU (1) AU759203B2 (en)
CA (1) CA2375207A1 (en)
HK (1) HK1042307A1 (en)
WO (1) WO2000078805A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (en) 1998-09-25 2001-11-28 格利科克斯有限公司 Fructosamine oxidase: antagonists and inhibitors
EP1487431B1 (en) 2002-03-08 2012-05-02 PhilERA New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2003281842A1 (en) * 2002-08-01 2004-02-23 Auckland Uniservices Limited Preptin methods of use
WO2004012761A1 (en) * 2002-08-01 2004-02-12 Protemix Corporation Limited Methods of use of compounds with preptin function
MXPA05002883A (en) 2002-08-20 2005-10-05 Protemix Corp Ltd Dosage forms and related therapies.
PT1778618E (en) 2004-07-19 2014-03-04 Philera New Zealand Ltd Synthesis of triethylenetetramines
JP2008538501A (en) * 2005-04-20 2008-10-30 オークランド ユニサービシーズ リミティド Vesiculin
CN102369015A (en) * 2009-02-02 2012-03-07 雷蒙特亚特特拉维夫大学有限公司 Peptides, pharmaceutical compositions comprising same and uses thereof
US8901074B2 (en) 2010-08-04 2014-12-02 Ramot At Tel-Aviv University Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000619A1 (en) * 1984-07-13 1986-01-30 Chiron Corporation Prepro insulin-like growth factors i and ii

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
ATE128359T1 (en) * 1988-01-11 1995-10-15 Amylin Pharmaceuticals Inc TREATMENT OF DIABETES MELLITUS TYPE 2.
ATE128032T1 (en) * 1989-07-10 1995-10-15 Amylin Pharmaceuticals Inc USE OF AN AMYLIN ANTAGONIST IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY AND ESSENTIAL HYPERTENSION AND RELATED DISEASES.
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000619A1 (en) * 1984-07-13 1986-01-30 Chiron Corporation Prepro insulin-like growth factors i and ii

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BUCHANAN C M ET AL: "Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion.", THE BIOCHEMICAL JOURNAL. 1 DEC 2001, vol. 360, no. Pt 2, 1 December 2001 (2001-12-01), pages 431 - 439, XP002359658, ISSN: 0264-6021 *
DUGUAY S.J. ET AL: "Post-translational Processing of the Insulin-like Growth Factor-2 Precursor. Analysis of O-Glycosylation and Endoproteolysis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 29, 17 July 1998 (1998-07-17), pages 18443 - 18451, XP002159286 *
GAMMELTOFT S ET AL.: "Insulin-like growth factors and insulin: gene expression, receptors and biological actions.", 1989, ELLIS HORWOOD LTD, CHICHESTER, XP009096156 *
HAGIWARA KOICHI ET AL: "Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer cells: Its identity with insulin-like growth factor II", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 86, no. 2, 1995, pages 202 - 207, XP009058818, ISSN: 0910-5050 *
HINTZ R.L. ET AL: "Development of a radioimmunoassay specific for the E peptide region of insulin-like growth factor II.", CLINICAL RESEARCH, vol. 35, no. 3, 1987, XP009096228 *
HYLKA V.W. ET AL: "Identification of a peptide fragment from the carboxyl-terminal extension region (E-domain) of rat proinsulin-like growth factor-II.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 260, no. 27, 25 November 1985 (1985-11-25), pages 14417 - 14420 *
PERDUE J F ET AL.: "Development of a specific radioimmunoassayfor E domain containing forms of insulin-like growth factor II.", 1991, NEW YORK, XP009096227 *
RECHLER M M ET AL: "CHARACTERIZATION OF THE BIOSYNTHETIC PRECURSOR FOR RAT INSULIN-LIKE GROWTH FACTOR II BY BIOSYNTHETIC LABELING RADIOSEQUENCING AND NUCLEOTIDE SEQUENCE ANALYSIS OF A COMPLEMENTARY DNA CLONE", FERAMISCO, J., B. OZANNE AND C. STILES (ED.). CANCER CELLS (COLD SPRING HARBOR), VOL. 3. GROWTH FACTORS AND TRANSFORMATION; MEETING, COLD SPRING HARBOR, N.Y., USA. XVII+450P. COLD SPRING HARBOR LABORATORY: COLD SPRING HARBOR, N.Y., USA. ILLUS. PAPER, 1985, pages 131 - 138, XP009058812, ISSN: 0-87969-178-6 *
See also references of WO0078805A1 *
STEMPIEN M M ET AL: "SEQUENCE OF A PLACENTAL COMPLEMENTARY DNA ENCODING THE MOUSE INSULIN-LIKE GROWTH FACTOR II PRECURSOR", DNA (NEW YORK), vol. 5, no. 5, 1986, pages 357 - 362, XP009058819, ISSN: 0198-0238 *
SWOPE S.L. ET AL: "Bombesin stimulates insuline secretion by a pancreatic islet cell line.", PROC NATL ACAD SCI USA, vol. 81, March 1984 (1984-03-01), pages 1822 - 1826 *
TATEMOTO K ET AL: "PANCREASTATIN NOVEL PANCREATIC PEPTIDE THAT INHIBITS INSULIN SECRETION", NATURE (LONDON), vol. 324, no. 6096, 1986, pages 476 - 478, XP001207842, ISSN: 0028-0836 *
WAEBER G ET AL: "INSULIN SECRETION IS REGULATED BY THE GLUCOSE-DEPENDENT PRODUCTION OF ISLET BETA CELL MACROPHAGE MIGRATION INHIBITORY FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, 1997, pages 4782 - 4787, XP000882991, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2003503019A (en) 2003-01-28
AU759203B2 (en) 2003-04-10
WO2000078805A1 (en) 2000-12-28
CA2375207A1 (en) 2000-12-28
HK1042307A1 (en) 2002-08-09
AU5717800A (en) 2001-01-09
EP1185558A1 (en) 2002-03-13
CN1355813A (en) 2002-06-26
CN1296384C (en) 2007-01-24

Similar Documents

Publication Publication Date Title
PL344341A1 (en) Peptides
GB0014870D0 (en) Peptides
GB9912852D0 (en) Peptides
EP1173467A4 (en) Chemokine-derived synthetic peptides
GB9918156D0 (en) Synthetic peptides
GB9825854D0 (en) Peptide
GB0029777D0 (en) Peptides
HK1042307A1 (en) Peptide having preptin functionality
EP1147130A4 (en) Alpha-conotoxin peptides
GB9812675D0 (en) Peptides
GB9904695D0 (en) Peptide
EP1159288A4 (en) Alpha-conotoxin peptides
GB9908920D0 (en) Peptide
GB0001825D0 (en) Peptides
IL144376A0 (en) Peptides
HK1045173A1 (en) Polypeptide
GB9807890D0 (en) Peptides
EP1151100A4 (en) Tau-conotoxin peptides
GB0007263D0 (en) Peptides
GB9907216D0 (en) Peptide
GB9917565D0 (en) Peptide
GB9918680D0 (en) Polypeptide
GB9907911D0 (en) Peptides
GB9928325D0 (en) Peptides
GB9918606D0 (en) Novel peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: COOPER, GARTH, JAMES, SMITH

Inventor name: BUCHANAN, CHRISTINA, MAREE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEMIX CORPORATION LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEMIX DISCOVERY LIMITED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/10 20060101ALI20051220BHEP

Ipc: C07K 7/04 20060101ALI20051220BHEP

Ipc: C07K 14/65 20060101AFI20051220BHEP

Ipc: A61K 38/30 20060101ALI20051220BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1042307

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100105